{
    "Clinical Trial ID": "NCT03069313",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Arm I",
        "  Oral Vitamin B12",
        "  Vitamin B12: Vitamin B12 2500 micrograms sublingually per day over the course of 90 days (+/- 10 days)"
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Sign informed consent and Pain level > 4 in the BPI scale,",
        "  Stage I-III",
        "Exclusion Criteria:",
        "  <18 yrs",
        "  Stage IV",
        "  BPI Score <4",
        "Zubrod score >2"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Percentage Change in Average Joint Pain in Women With Aromatase Inhibitor-associated Musculoskeletal Symptoms (AIMSS) Compared to Baseline as Measured by the Brief Pain Inventory Short Form (BPI-SF).",
        "  The Brief Pain Inventory - Short Form (BPI- SF) average pain score used. This item has a scale of 0 to 10 with 0 indicating \"No pain\" and 10 indicating \"Pain as bad as you can imagine\" We expect at least 20% improvement in BPI-SF pain scores. Participants were asked to rate worst pain an average pain within the last 24 hours.",
        "  Time frame: Baseline and 90 days (+/- 10 days)",
        "Results 1: ",
        "  Arm/Group Title: Arm I",
        "  Arm/Group Description: Oral Vitamin B12",
        "  Vitamin B12: Vitamin B12 2500 micrograms sublingually per day over the course of 90 days (+/- 10 days)",
        "  Overall Number of Participants Analyzed: 36",
        "  Mean (Standard Deviation)",
        "  Unit of Measure: Percentage change  -33.8         (34.1)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 0/36 (0.00%)"
    ]
}